Business Wire

The Game-Changing Wireless Mouse: Higround’s YUMA is Designed for Style and Performance

9.9.2024 22:50:00 CEST | Business Wire | Press release

Share

Higround, the premier lifestyle and graphic gaming peripheral brand, is thrilled to announce its first-ever wireless gaming mouse: YUMA. Lightweight, meticulously designed, and built to perform, YUMA marks a new chapter in Higround’s mission to elevate every aspect of your gaming setup into a true expression of individual artistry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909711165/en/

The YUMA mouse launches with two colorways: RADAR and CELSHADE. (Photo: Business Wire)

Meet YUMA: Where Art Meets Performance

Every wireless mouse features hand-applied graphic artwork, ensuring that each mouse is fine-tuned to the minutest detail. It’s a true collector’s item that reflects Higround’s commitment to individuality and creative expression. Weighing in at just 49 grams, YUMA is a game-changer in the world of gaming mice, combining top-tier performance with unparalleled design aesthetics. With two distinct designs—RADAR and CELSHADE—the YUMA collection brings bold, unique visuals to your fingertips.

YUMA is more than just an aesthetically pleasing mouse; it packs serious gaming performance, featuring a 4KHz wireless polling rate for ultra-responsive, lag-free gameplay. Every click and movement registers with pinpoint accuracy, giving users the competitive edge they need to rise to the top.

Equipped with a battery life of up to 70 hours, YUMA ensures you stay in the game longer without the worry of frequent recharges. Whether you’re a casual gamer or a competitive esports player, YUMA delivers the reliability and performance you need while looking incredible on your desk.

Higround's Expansion Across the Desk Setup

With the introduction of YUMA, Higround continues its mission to transform every piece of your gaming setup into a canvas for personal expression. "We started Higround with the belief that your setup is an extension of who you are," says Rustin Sotoodeh, CEO and Creative Director of Higround. "With YUMA, we’re expanding Higround’s reach onto an even more technical piece of hardware, giving gamers a mouse that not only performs at the highest level but also stands out as a unique work of art."

“We're excited to introduce our new YUMA mouse, engineered with performance in mind and infused with our distinctive visual style,” says Higorund’s Principal Product Manager, Jeff Chang. “This release marks a significant step for Higround and we can't wait to show off our unique vision to the world.”

YUMA launches with its debut designs—RADAR and CELSHADE— on September 13 at 12 PM PT exclusively on Higround.

ABOUT HIGROUND

Higround is a lifestyle and computer peripheral brand that is the expression of elevated gaming culture. Founded by Rustin Sotoodeh and Kha Lu, Higround creates high-quality peripherals with unique designs that call back to the overarching cultures of fashion, gaming, and technology. Each collection features a unique collection of items that add personality to computer setups that are known to sell out in an instant. The brand is widely known for collaborations with iconic brands such as Pokemon, Beats by Dre, and One Piece. With their expansion into mice, Higround continues its journey to take over your gaming setup—one peripheral at a time. In 2021 the brand was acquired by esports giant, 100 Thieves.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909711165/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye